Trials comparing bare metal stents with CABG (results for diabetic subgroup)
| Trial | Period | Primary endpoint | Number of patients | Proportion of diabetics | Primary end point in diabetics |
|---|---|---|---|---|---|
| ERACI II32 | 1996–1998 | MACE | 450 | 17.3% in both groups | Thirty-day outcomes: similar in both PCI and CABG Five-year mortality: PCI diabetic vs non-diabetic:10.0% vs 5.6% (p=NS) CABG diabetic vs non-diabetic 10.2% vs 11.6% (p=NS) |
| SOS33 | 1996–1999 | Repeat revascularisation | 988 | <6.0% | n/a |
| ARTS34 35 | 1997–1998 | Freedom from MACCE at 1 year | 1205 | PCI: 19% CABG: 16% | PCI: 63.4% CABG: 84.4% p=0.001 |
| AWESOME36 | 1996–2000 | Survival at 3 and 5 years | 454 randomised group | 32% in randomised group | Three-year survival: 72% vs 81% (p=NS) Five-year freedom from repeat revascularisation/unstable angina: CABG: 54% vs PCI: 49% |
ARTS, Arterial Revascularization Therapies Study; CABG, coronary artery bypass grafting; MACCE, major adverse cardiac and cerebrovascular events; PCI, percutaneous coronary interventions.